A spin-off from University of Arizona College of Medicine, Fibronox, LLC, was orginally formed to address development of a small molecule inhibitor (Nox4) to treat life-threatening scarring - fibrotic disorders to include lung fibrosis. Research to date has led to the first highly selective Nox4 small molecule inhibitors for the treatment of such cinditions through reduction of oxidative stress. Such fibrotic disorders - the progressive buildup of scar tissue - can occur throughout the body and are typically chronic and possibly fatal.
